The Shakeout of 2020: The Year That Small Changes Emerge From the Big Hype

Posted by Brian Chapman on January 13, 2020

With a new year and a new decade underway, it’s a great time to trot out my latest healthcare predictions. Perhaps one of the areas that healthcare’s transformation will be most evident is in the transfer of power across care settings. In the US, hospitals will lose a high number of orthopedic and cardiac procedures—and their corresponding profits—to ambulatory settings. Headline-grabbing trends like AI, big data and robotics are on the list, too, and although their individual impact on the sector will be meaningful, it likely won’t measure up to the hype. Finally, medtech will take advantage of the decade’s fresh start by modernizing its business approach and finally entering the digital age. Here’s how these five trends will alter the way that medtech companies do business and make decisions in the coming years.


>
Read More

Reversing Medtech Price Erosion

Posted by Brian Chapman on September 5, 2019

This blog post is the second in a two-part series about what’s behind price erosion in medtech and how to reverse it.

Medtech is dealing with forces that have been eroding profitability. As companies look to repair this price erosion, they’ll need to adopt a more comprehensive approach to pricing governance and execution, which includes leveraging data and analytics to improve their pricing and contracting strategies.


>
Read More

What’s Driving Medtech Price Erosion?

Posted by Brian Chapman on September 3, 2019

This blog post is the first in a two-part series about what’s behind price erosion in medtech and how to reverse it.

Medtech leaders today face several headwinds that are threatening to erode price and profitability. Some of these forces are external—like the professionalization of purchasing, provider consolidation, a changing buying center and increased focus on product value—but others are internal habits and mindsets that are long overdue for a change. In our next post, we’ll discuss how medtech leaders have begun to address these challenges, but before we do, let’s define their root causes.


>
Read More

Dear Medtech: I’m Not Sick, So Why Do You Keep Calling Me a ‘Patient’?

Posted by Brian Chapman on May 17, 2019

Mick Jagger, The Rolling Stones’ 75-year-old lead singer, recently underwent a transcatheter aortic valve replacement procedure. A look at his Twitter feed shows a total of two tweets dedicated to this episode of care: First, he expressed his dismay at postponing the North American leg of his band’s tour and then, after a brief Twitter hiatus, he said that he’s feeling better and thanked the hospital staff. Do you think that the king of swagger wants to be considered a “patient” outside of this encounter? Not a chance.


>
Read More

What It Takes for Multinational Medtech Companies to Succeed in China

Posted by ZS Editors on April 9, 2019

With a population of 1.4 billion, China is a market that most medtech companies can’t afford to ignore. However, differences in population types (urban versus rural), the government’s role in healthcare expansion and a multi-tiered distribution system that is undergoing reform make navigating the Chinese market a challenge.


>
Read More